About Rayyan Therapeutics Inc.
At Rayyan Therapeutics, we are committed to revolutionizing stroke care through innovative therapies that extend treatment windows and improve patient outcomes. Our research focuses on developing safer and more effective thrombolytic treatments that address the critical gaps in current stroke therapies. By combining advanced science with a patient-first approach, we aim to provide stroke survivors with better recovery options and enhanced quality of life.
We are proud to be at the forefront of medical innovation, driven by a team of experts dedicated to making meaningful advancements in stroke treatment. Our therapies are designed to overcome the limitations of traditional treatments, offering a safer, more precise solution to ischemic strokes. We believe in pushing the boundaries of science for the benefit of those who need it most, empowering patients with hope and a better tomorrow.
Our Focus Areas
Novel Stroke Treatment Platform
The Rayyan therapy is a proprietary, non-immunogenic form of stabilized ADAMTS13 that enhances clot dissolution without increasing bleeding risk. By overcoming key limitations of current thrombolytics, it offers a safer and more precise solution for treating ischemic stroke.
